Bioceramic Particle Matrix for Autologous Bone Graft Substitutes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bone graft substitutes face challenges in providing an optimal carrier system for bone morphogenetic proteins (BMPs), including compressibility, rapid resorption, and immunogenicity, which affect the efficacy and safety of bone formation and fusion in spinal procedures.
Innovation Solution
An Autologous Bone Graft Substitute Composition comprising bioceramic particles with defined particle size and geometry, combined with autologous blood coagulum, serves as a compression-resistant matrix to sustainably release BMPs, promoting bone induction and avoiding immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous bone graft is used as gold standard for spinal fusion, then osteoconductivity and osteogenicity are improved, but donor site morbidity and limited bone availability worsen
Solution Approach 1:
The patent uses an intermediary carrier system (collagen sponge or hydrogel matrix) to deliver bone morphogenetic proteins and osteogenic cells to the implant site, replacing the need for autologous bone harvesting while maintaining osteoinductive and osteoconductive properties
Solution Approach 2:
The invention creates a synthetic copy of the natural bone graft function by combining BMPs, osteogenic cells, and a biodegradable matrix that mimics the osteoinductive and osteoconductive properties of autologous bone without requiring donor site harvesting
2Reliability
If bone morphogenetic proteins are used to promote bone formation, then osteoinductivity is improved, but carrier compressibility and rapid resorption worsen
Solution Approach 1:
The patent employs composite material systems combining collagen sponges or hydrogels with bioceramics (hydroxyapatite, beta-tricalcium phosphate) to create a matrix that provides both mechanical stability and controlled BMP release, preventing rapid resorption while maintaining osteoinductivity
Solution Approach 2:
The invention modifies the physical and chemical parameters of the carrier matrix by adjusting crosslinking density, porosity, and composition ratios to control compression resistance and BMP release kinetics, achieving sustained delivery without rapid degradation
3Quantity of substance
If allograft is used as bone substitute, then bone availability is improved, but immunogenicity and infection risk worsen
Solution Approach 1:
The patent uses synthetic biodegradable polymers and bioceramics as intermediary materials that provide structural support and BMP delivery without elicits immune response or infection risk, replacing allograft while maintaining bone availability through controlled BMP-induced osteogenesis
4Strength
If bioceramic particles with large size are used for compression resistance, then mechanical strength is improved, but surface area for BMP binding worsens
Solution Approach 1:
The patent applies local quality by using a bimodal particle size distribution where larger particles (2-4 mm) provide compression resistance in the bulk, while smaller particles (50-250 μm) coat the surfaces and fill interstices to maximize BMP binding area, achieving both mechanical strength and high surface area availability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves effective bone formation and fusion with improved biomechanical properties, reduced immunogenicity, and prolonged sustainability, enhancing the safety and efficacy of spinal fusion procedures.
Implementation Method 1
bioceramic particles of different geometry... having a significant role as a compression resistant matrix
Implementation Method 2
autologous blood coagulum... as carrier for an osteogenic bone morphogenetic protein
Implementation Method 3
surface area, pore volume and particle size of said bioceramic particles
Data Source
AI summary
An autologous bone graft substitute composition for inducing new bone formation, promoting bone growth and treating bone defects. The composition includes autologous blood; one or more analogs of an osteogenic bone morphogenetic protein selected from BMP-6, BMP-2, BMP-7, BMP-4, BMP-5, BMP-8, BMP-9, BMP-12, and BMP-13, and combinations thereof in a range of from 2 to 1000 μg per ml of autologous blood; and hydroxyapatite, tri-calcium phosphate, or a mixture thereof as a compression resistant matrix, the compression resistant matrix being provided in the form of particles having a particle size in a range of from above 74 to 8000 μm. Preferably, a ratio between the compression resistant matrix and the autologous blood coagulum is from 50 to 500 mg of the compression resistant matrix per mL of the autologous blood coagulum.